Ralimetinib is an ATP-competitive p38alpha and p38beta MAPK inhibitor with an IC50 of 5.3 nmol/L against human p38alpha and an IC50 of 3.2 nmol/L against human p38beta. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma[1][2].
Molekulargewicht:
420.53
Reinheit:
98.58
CAS Nummer:
[862505-00-8]
Formel:
C24H29FN6
Target-Kategorie:
Autophagy,p38 MAPK
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
